Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer.

Détails

ID Serval
serval:BIB_F170F432E72A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer.
Périodique
Clinical cancer research
Auteur(s)
Ciarloni L., Ehrensberger S.H., Imaizumi N., Monnier-Benoit S., Nichita C., Myung S.J., Kim J.S., Song S.Y., Kim T.I., van der Weg B., Meier R., Borovicka J., Beglinger C., Vallet C., Maerten P., Rüegg C., Dorta G.
ISSN
1078-0432 (Print)
ISSN-L
1078-0432
Statut éditorial
Publié
Date de publication
15/09/2016
Peer-reviewed
Oui
Volume
22
Numéro
18
Pages
4604-4611
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
A blood test for early detection of colorectal cancer is a valuable tool for testing asymptomatic individuals and reducing colorectal cancer-related mortality. The objective of this study was to develop and validate a novel blood test able to differentiate patients with colorectal cancer and adenomatous polyps (AP) from individuals with a negative colonoscopy.
A case-control, multicenter clinical study was designed to collect blood samples from patients referred for colonoscopy or surgery. Predictive algorithms were developed on 75 controls, 61 large AP (LAP) ≥1 cm, and 45 colorectal cancer cases and independently validated on 74 controls, 42 LAP, and 52 colorectal cancer cases (23 stages I-II) as well as on 245 cases including other colorectal findings and diseases other than colorectal cancer. The test is based on a 29-gene panel expressed in peripheral blood mononuclear cells alone or in combination with established plasma tumor markers.
The 29-gene algorithm detected colorectal cancer and LAP with a sensitivity of 79.5% and 55.4%, respectively, with 90.0% specificity. Combination with the protein tumor markers carcinoembryonic antigen (CEA) and CYFRA21-2 resulted in a specificity increase (92.2%) with a sensitivity for colorectal cancer and LAP detection of 78.1% and 52.3%, respectively.
We report the validation of a novel blood test, Colox®, for the detection of colorectal cancer and LAP based on a 29-gene panel and the CEA and CYFRA21-1 plasma biomarkers. The performance and convenience of this routine blood test provide physicians a useful tool to test average-risk individuals unwilling to undergo upfront colonoscopy. Clin Cancer Res; 22(18); 4604-11. ©2016 AACR.

Mots-clé
Adenomatous Polyps/blood, Adenomatous Polyps/diagnosis, Adenomatous Polyps/genetics, Aged, Algorithms, Biomarkers, Tumor, Case-Control Studies, Colonoscopy, Colorectal Neoplasms/blood, Colorectal Neoplasms/diagnosis, Colorectal Neoplasms/epidemiology, Colorectal Neoplasms/genetics, Comorbidity, DNA, Neoplasm/blood, DNA, Neoplasm/genetics, Early Detection of Cancer/methods, Early Detection of Cancer/standards, Female, Humans, Liquid Biopsy, Male, Middle Aged, Neoplasm Staging, Reproducibility of Results, Sensitivity and Specificity
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/10/2016 13:21
Dernière modification de la notice
20/08/2019 16:18
Données d'usage